Intellia Therapeutics (NASDAQ:NTLA) issued its earnings results on Thursday. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.05, Morningstar.com reports. The business had revenue of $11.10 million during the quarter, compared to the consensus estimate of $7.15 million. Intellia Therapeutics had a negative return on equity of 31.68% and a negative net margin of 257.28%. The company’s revenue for the quarter was up 44.2% on a year-over-year basis. During the same period in the prior year, the business posted ($0.52) EPS.
NASDAQ:NTLA traded down $0.01 during trading hours on Thursday, reaching $18.09. 836,700 shares of the company traded hands, compared to its average volume of 588,350. The firm’s 50-day simple moving average is $16.22. The stock has a market capitalization of $815.01 million, a PE ratio of -9.14 and a beta of 2.62. The company has a debt-to-equity ratio of 0.06, a quick ratio of 7.74 and a current ratio of 7.74. Intellia Therapeutics has a 1-year low of $11.03 and a 1-year high of $32.95.
A number of equities research analysts recently weighed in on NTLA shares. Chardan Capital restated a “buy” rating and issued a $57.50 price target on shares of Intellia Therapeutics in a report on Tuesday, May 28th. Zacks Investment Research cut Intellia Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, July 10th. BidaskClub upgraded Intellia Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, June 20th. Roth Capital started coverage on Intellia Therapeutics in a report on Monday, June 10th. They issued a “neutral” rating and a $16.00 price target on the stock. Finally, Evercore ISI started coverage on Intellia Therapeutics in a report on Thursday, April 11th. They issued an “outperform” rating on the stock. Eight research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Intellia Therapeutics currently has a consensus rating of “Hold” and an average price target of $25.31.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.
Featured Story: What is the Beige Book?
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.